Xenon Pharma director granted RSUs and options

Xenon Pharmaceuticals Inc. director Gillian Cannon reported routine equity compensation and an option exercise.

Rhea-AI Filing Summary

Xenon Pharmaceuticals Inc. director Gillian Cannon reported routine equity compensation and an option exercise. She received 1,593 Restricted Share Units and 10,507 share options with an exercise price of $53.4600 per share, each tied to future vesting. Separately, 2,645 RSUs granted on June 5, 2025 fully vested on June 1, 2026 and were settled into an equal number of common shares. The new RSU grant and options vest 100% on the earlier of June 1, 2027 or the day before the company’s 2027 annual meeting of shareholders.

Insider Trade Summary

2,645 shares exercised/converted

Exercise 4 txns

Insider Cannon Gillian

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	10,507	$0.00	$0.00
Grant/Award	Restricted Share Units	1,593	$0.00	$0.00
Exercise	Restricted Share Units	2,645	$0.00	$0.00
Exercise	Common Shares	2,645	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 10,507 contracts (Direct); Restricted Share Units — 1,593 contracts (Direct); Common Shares — 2,645 shares (Direct)

Footnotes (3)

1. F1. Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
2. F2. Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
3. F3. Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

Key Figures

New RSU grant: 1,593 units New options granted: 10,507 options Option exercise price: $53.4600 per share +2 more

5 metrics

New RSU grant 1,593 units Restricted Share Units granted to director on June 3, 2026

New options granted 10,507 options Share Option (Right to Buy) granted on June 3, 2026

Option exercise price $53.4600 per share Exercise price for 10,507 share options expiring June 2, 2036

RSUs vested into shares 2,645 common shares RSUs from June 5, 2025 award vested on June 1, 2026

Future vesting date June 1, 2027 Awards vest earlier of June 1, 2027 or day before 2027 AGM

Key Terms

Restricted Share Units, Share Option (Right to Buy), annual meeting of shareholders, Exercise or conversion of derivative security

4 terms

Restricted Share Units financial

"Represents Common Shares earned and vested under a restricted share unit ("RSU") award"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

Share Option (Right to Buy) financial

"security_title": "Share Option (Right to Buy)""

annual meeting of shareholders financial

"the day before the date of the issuer's 2027 annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Xenon Pharmaceuticals (XENE) report for Gillian Cannon?

Xenon Pharmaceuticals reported that director Gillian Cannon received new equity awards and exercised RSUs. She was granted 1,593 RSUs, 10,507 share options, and had 2,645 RSUs vest into common shares on June 1, 2026.

How many share options were granted to Xenon Pharmaceuticals (XENE) director Gillian Cannon?

Gillian Cannon received 10,507 share options as part of her compensation. These options carry an exercise price of $53.4600 per share and are scheduled to vest 100% on the earlier of June 1, 2027 or the day before the 2027 annual shareholder meeting.

What are the key terms of the new RSU grant at Xenon Pharmaceuticals (XENE)?

The new award consists of 1,593 Restricted Share Units. Each RSU converts into one common share and vests 100% on the earlier of June 1, 2027 or the day before Xenon Pharmaceuticals’ 2027 annual meeting of shareholders, aligning director compensation with long-term performance.

What happened to the 2025 RSU award reported by Xenon Pharmaceuticals (XENE)?

An RSU award granted on June 5, 2025 fully vested on June 1, 2026. As a result, 2,645 RSUs converted into 2,645 common shares, reflecting delivery of previously granted equity compensation to director Gillian Cannon at the scheduled vesting date.

When do Gillian Cannon’s new Xenon Pharmaceuticals (XENE) equity awards vest?

Both the 1,593 RSUs and 10,507 share options vest in full on a single date. Vesting occurs on the earlier of June 1, 2027 or the day before Xenon Pharmaceuticals’ 2027 annual meeting of shareholders, as specified in the award terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 09:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cannon Gillian

(Last) (First) (Middle)

3650 GILMORE WAY

(Street)

BURNABY CANADA (FEDERAL LEVEL) V5G 4W8

(City) (State) (Zip)

CANADA (FEDERAL LEVEL)

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xenon Pharmaceuticals Inc. [ XENE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/01/2026		M		2,645(1)	A	(1)	2,645	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	06/01/2026		M			2,645	(1)	(1)	Common Shares	2,645	$0	0	D
Share Option (Right to Buy)	$53.46	06/03/2026		A		10,507		(2)	06/02/2036	Common Shares	10,507	$0	10,507	D
Restricted Share Units	$0	06/03/2026		A		1,593		(3)	(3)	Common Shares	1,593	$0	1,593	D

Explanation of Responses:

1. Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

2. Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

3. Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

	/s/ Nathaniel Adams, Attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)